Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.

RATIONALE Forced vital capacity (FVC) is an established measure of pulmonary function in idiopathic pulmonary fibrosis (IPF). Evidence regarding its measurement properties and minimal clinically important difference (MCID) in this population is limited. OBJECTIVES To assess the reliability, validity, and responsiveness of FVC and estimate the MCID in patients with IPF. METHODS The study population included all 1,156 randomized patients in two clinical trials of IFN-γ1b. FVC and other measures of functional status were measured at screening or baseline and 24-week intervals thereafter. Reliability was assessed based on two proximal measures of FVC, validity was assessed based on correlations between FVC and other measures of functional status, and responsiveness was assessed based on the relationship between 24-week changes in FVC and other measures of functional status. Distribution-based and anchor-based methods were used to estimate the MCID. MEASUREMENTS AND MAIN RESULTS Correlation of percent-predicted FVC between measurements (mean interval, 18 d) was high (r = 0.93; P < 0.001). Correlations between FVC and other parameters were generally weak, with the strongest observed correlation between FVC and carbon monoxide diffusing capacity (r = 0.38; P < 0.001). Correlations between change in FVC and changes in other parameters were slightly stronger (range, r = 0.16-0.37; P < 0.001). Importantly, 1-year risk of death was more than twofold higher (P < 0.001) in patients with a 24-week decline in FVC between 5% and 10%. The estimated MCID was 2-6%. CONCLUSIONS FVC is a reliable, valid, and responsive measure of clinical status in patients with IPF, and a decline of 2-6%, although small, represents a clinically important difference.

[1]  Russian Federation.,et al.  European Respiratory Society Annual Congress 2013 , 2013 .

[2]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[3]  S. Sahn,et al.  Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. , 2011, American journal of respiratory and critical care medicine.

[4]  H. Collard,et al.  Clinical course and prediction of survival in idiopathic pulmonary fibrosis. , 2011, American journal of respiratory and critical care medicine.

[5]  G. Raghu,et al.  Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. , 2010, American journal of respiratory and critical care medicine.

[6]  D. Fairclough,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2010, European Respiratory Journal.

[7]  A. Nicholson,et al.  Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[8]  A. Holland,et al.  Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. , 2009, Respiratory medicine.

[9]  S. Sahn,et al.  Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial , 2009, The Lancet.

[10]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis: A phase III clinical trial in Japan , 2009 .

[11]  J. Epstein,et al.  Separating gains and losses in health when calculating the minimum important difference for mapped utility measures , 2008, Quality of Life Research.

[12]  Malcolm Man-Son-Hing,et al.  Determination of the clinical importance of study results , 2002, Journal of General Internal Medicine.

[13]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[14]  D. Eton,et al.  Combining Distribution- and Anchor-Based Approaches to Determine Minimally Important Differences , 2005, Evaluation & the health professions.

[15]  S. Kudoh,et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.

[16]  W. Travis,et al.  Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. , 2005, American journal of respiratory and critical care medicine.

[17]  G. Guyatt,et al.  Commentary--goodbye M(C)ID! Hello MID, where do you come from? , 2005, Health services research.

[18]  A. Ries,et al.  Minimally Clinically Important Difference for the UCSD Shortness of Breath Questionnaire, Borg Scale, and Visual Analog Scale , 2005, COPD.

[19]  G. Raghu,et al.  Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. , 2005, Chest.

[20]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[21]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[22]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[23]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[24]  J. Brazier,et al.  What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D , 2003, Health and quality of life outcomes.

[25]  Gordon H Guyatt,et al.  Methods to explain the clinical significance of health status measures. , 2002, Mayo Clinic proceedings.

[26]  J. Tooze,et al.  Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. , 2001, American journal of respiratory and critical care medicine.

[27]  Arnold Simanowitz,et al.  international consensus statement , 2000 .

[28]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[29]  G. Raghu,et al.  Assessment of health-related quality of life in patients with interstitial lung disease. , 1999, Chest.

[30]  W. Tierney,et al.  Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. , 1999, Journal of clinical epidemiology.

[31]  W M Tierney,et al.  Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. , 1999, Medical care.

[32]  R. Kaplan,et al.  Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. , 1998, Chest.

[33]  R. Kaplan,et al.  The UCSD Shortness of Breath Questionnaire , 1998 .

[34]  P. Allison Survival analysis using the SAS system : a practical guide , 1995 .

[35]  P. Lachenbruch Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .